CHF6001 DPI (Tanimilast)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CHF6001 DPI (Tanimilast), covering 2025-12-17 to 2025-12-17. Get the full timeline:
Most recent: Clinical Trial Update: A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) [Phase 3]